BACKGROUND: The metabolic syndrome (MetS) is associated with cognitive deficits and atherosclerotic vascular disease. We examined whether the relation between the MetS and cognitive dysfunction is mediated by measures of atherosclerosis or the presence of clinically manifest cardiovascular disease. METHODS: In 380 individuals (153 with MetS; 60-87 years) from the population based Hoorn Study, measures of atherosclerosis including carotid intima-media thickness (c-IMT), flow mediated dilation (FMD), ankle-brachial index and the presence of clinically manifest cardiovascular disease were assessed at baseline and 7 later years at follow-up. Cognitive functioning (information processing speed, memory, and attention and executive functioning) was assessed at follow-up. The relation between the MetS, atherosclerosis and cognitive functioning was assessed with linear regression analysis. RESULTS: Individuals with MetS showed worse performance on information processing speed (adjusted mean difference z-score ± SE: -0.22 ± 0.6; p = 0.01) and attention and executive functioning (-0.32 ± 0.07; p < 0.001), but not on the domain memory. The affected cognitive domains were also associated with measures of atherosclerosis (standardised B (95%CI) c-IMT: -0.14 (-0.24; -0.05); p < 0.01; FMD: 0.13 (0.02; 0.24), p < 0.05) and a history of clinically manifest cardiovascular disease: (-0.29 (-0.47; -0.11); p < 0.01). However, the relation between the MetS and cognitive functioning did not change after adjustment for c-IMT, FMD or a history of clinically manifest cardiovascular disease (p > 0.05). CONCLUSION: In this population based cohort, the relation between the MetS and cognitive dysfunction was not mediated by atherosclerosis or a history of cardiovascular disease. These findings should stimulate future studies to elucidate alternative mechanisms underlying cognitive deficits in individuals with MetS.
BACKGROUND: The metabolic syndrome (MetS) is associated with cognitive deficits and atherosclerotic vascular disease. We examined whether the relation between the MetS and cognitive dysfunction is mediated by measures of atherosclerosis or the presence of clinically manifest cardiovascular disease. METHODS: In 380 individuals (153 with MetS; 60-87 years) from the population based Hoorn Study, measures of atherosclerosis including carotid intima-media thickness (c-IMT), flow mediated dilation (FMD), ankle-brachial index and the presence of clinically manifest cardiovascular disease were assessed at baseline and 7 later years at follow-up. Cognitive functioning (information processing speed, memory, and attention and executive functioning) was assessed at follow-up. The relation between the MetS, atherosclerosis and cognitive functioning was assessed with linear regression analysis. RESULTS: Individuals with MetS showed worse performance on information processing speed (adjusted mean difference z-score ± SE: -0.22 ± 0.6; p = 0.01) and attention and executive functioning (-0.32 ± 0.07; p < 0.001), but not on the domain memory. The affected cognitive domains were also associated with measures of atherosclerosis (standardised B (95%CI) c-IMT: -0.14 (-0.24; -0.05); p < 0.01; FMD: 0.13 (0.02; 0.24), p < 0.05) and a history of clinically manifest cardiovascular disease: (-0.29 (-0.47; -0.11); p < 0.01). However, the relation between the MetS and cognitive functioning did not change after adjustment for c-IMT, FMD or a history of clinically manifest cardiovascular disease (p > 0.05). CONCLUSION: In this population based cohort, the relation between the MetS and cognitive dysfunction was not mediated by atherosclerosis or a history of cardiovascular disease. These findings should stimulate future studies to elucidate alternative mechanisms underlying cognitive deficits in individuals with MetS.
Authors: Christina E Hugenschmidt; Fang-Chi Hsu; Satoru Hayasaka; J Jeffrey Carr; Barry I Freedman; David L Nyenhuis; Jeff D Williamson; Donald W Bowden Journal: J Diabetes Complications Date: 2013-05-07 Impact factor: 2.852
Authors: Angelo Scuteri; Pedro G Cunha; E Agabiti Rosei; Jolita Badariere; Sofie Bekaert; John R Cockcroft; Jorge Cotter; Francesco Cucca; Marc L De Buyzere; Tim De Meyer; Luigi Ferrucci; Osca Franco; Nichola Gale; Thierry C Gillebert; A Hofman; Michel Langlois; Aleksandras Laucevicius; Stephane Laurent; Francesco U S Mattace Raso; Cristopher H Morrell; Maria Lorenza Muiesan; Margaret M Munnery; Rokas Navickas; Pedro Oliveira; Marco Orru'; Maria Grazia Pilia; Ernst R Rietzschel; Ligita Ryliskyte; Massimo Salvetti; David Schlessinger; Nuno Sousa; Christodoulos Stefanadis; James Strait; Caroline Van Daele; Isabel Villa; Charalambos Vlachopoulos; Jacqueline Witteman; Panagiotis Xaplanteris; Peter Nilsson; Edward G Lakatta Journal: Atherosclerosis Date: 2014-01-30 Impact factor: 5.162
Authors: Rasa Kazlauskaite; Imke Janssen; Robert S Wilson; Bradley M Appelhans; Denis A Evans; Zoe Arvanitakis; Samar R El Khoudary; Howard M Kravitz Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: María I Herrera; Lucas D Udovin; Nicolás Toro-Urrego; Carlos F Kusnier; Juan P Luaces; Matilde Otero-Losada; Francisco Capani Journal: Front Neurosci Date: 2018-05-31 Impact factor: 4.677
Authors: Mahwesh Saleem; Nathan Herrmann; Adam Dinoff; Graham Mazereeuw; Paul I Oh; Benjamin I Goldstein; Alex Kiss; Prathiba Shammi; Krista L Lanctôt Journal: Psychosom Med Date: 2019 Feb/Mar Impact factor: 4.312